Else, L J <br/><br/>
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.  [electronic resource] 

 -  Antimicrobial agents and chemotherapy  Feb 2012 
 - 816-24 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1098-6596 
<br/><br/><label>Standard No.: </label>10.1128/AAC.05186-11  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Anti-HIV Agents--administration & dosage<br/>Biological Availability<br/>Capsules<br/>Cohort Studies<br/>Dose-Response Relationship, Drug<br/>Female<br/>Gelatin<br/>HIV Infections--drug therapy<br/>HIV Protease Inhibitors--administration & dosage<br/>Humans<br/>Lopinavir--administration & dosage<br/>Pregnancy<br/>Pregnancy Complications, Infectious--drug therapy<br/>Pregnancy Trimester, Second<br/>Pregnancy Trimester, Third<br/>Tablets<br/>Viral Load<br/>Young Adult